Achieving sufficient delivery across the blood–brain barrier is a key challenge in the
development of drugs to treat central nervous system (CNS) disorders. This is particularly …

The blood-brain barrier (BBB) prevents neurotoxic plasma components, blood cells, and
pathogens from entering the brain. At the same time, the BBB regulates transport of …

As an essential innate immune population for maintaining body homeostasis and warding
off foreign pathogens, macrophages display high plasticity and perform diverse supportive …

Cancer metastasis leads to high mortality of breast cancer and is difficult to treat because of
the poor delivery efficiency of drugs. Herein, we report the wrapping of a drug-carrying …

Neuronal mitochondrial dysfunction caused by excessive reactive oxygen species (ROS) is
an early event of sporadic Alzheimer's disease (AD), and considered to be a key pathologic …

The blood–brain barrier (BBB) is a highly specialized neurovascular unit, initially described
as an intact barrier to prevent toxins, pathogens, and potentially harmful substances from …

The existence of blood–brain barrier (BBB) hampers the effective treatment of central
nervous system (CNS) diseases. Almost all macromolecular drugs and more than 98% of …

Hepatic ischemia‐reperfusion injury (IRI), in which an insufficient oxygen supply followed by
reperfusion leads to an inflammatory network and oxidative stress in disease tissue to cause …

Most potent therapeutics are unable to cross the blood-brain barrier following systemic
administration, which necessitates the development of unconventional, clinically applicable …

Nucleic acid drugs have the advantages of rich target selection, simple in design, good and
enduring effect. They have been demonstrated to have irreplaceable superiority in brain …